ArticleBMC veterinary research2026
Immunomodulatory activities of bovine host defense peptides (HDPs): context-dependent roles in inflammation and immune priming.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Livestock immunomodulators as alternatives to antimicrobials - a roadmap for the fight against drug resistance.BMC veterinary research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMaintaining immune homeostasis is essential for livestock health and productivity, particularly in the face of infection or stress. Host defense peptides (HDPs), including β-defensins and cathelicidins, are key innate immune components with both antimicrobial and immunomodulatory properties. This study aimed to characterize the immunomodulatory effects of five bovine HDPs-BNBD1, BNBD3, LAP, Bac5, and BMAP27-on peripheral blood mononuclear cells (PBMCs) and bovine turbinate (BT) epithelial cells, under both basal and lipopolysaccharide (LPS)-stimulated inflammatory conditions. Cytokine secretion, cell viability, and real-time epithelial cell behavior were assessed to evaluate peptide-specific immune modulation.
resultsUnder non-stimulated conditions, LAP stimulated the secretion of IL-8 (LAP p < 0.0001). In LPS-stimulated PBMCs, prophylactic HDP treatment (4 h pre-LPS) amplified inflammatory cytokine secretion. BNBD3 and LAP significantly increased IL-1β, IL-6, TNF-α, IFN-γ (p < 0.05), and chemokines such as IL-8 and MIP-1α (p < 0.01), suggesting an immune-priming effect that may enhance responsiveness to subsequent LPS stimulation. Notably, BNBD3 and LAP failed to induce a comparable inflammation when added 0.5 h after LPS, highlighting the context-dependent nature of HDP action. Conversely, BMAP27 demonstrated anti-inflammatory activity by reducing LPS-induced IL-1β, IFN-γ, and IL-10 (p < 0.001), irrespective of timing. Bac5 increased IL-8 secretion (p < 0.001) and MCP-1 (p < 0.05), suggesting a chemotactic effect. Cell viability assays confirmed that none of the peptides exhibited cytotoxicity in PBMCs at tested concentrations, although BMAP27 reduced lymphocyte numbers (40% decrease, p < 0.0001), possibly indicating selective immunoregulatory effects. In BT cells, Bac5 enhanced proliferation (11% increase, p < 0.05), while BNBD1 (23% decrease, p < 0.01) and BMAP27 (10% decrease, p < 0.05) mildly reduced cellular impedance, reflecting divergent impacts on epithelial dynamics.
conclusionsThese findings reveal distinct immunomodulatory profiles among bovine HDPs, ranging from pro-inflammatory (BNBD3, LAP) to suppressive (BMAP27), and underscore the importance of treatment timing. The immune-priming capacity of certain HDPs suggests potential use as prophylactic agents to enhance resilience to infections, while suppressive peptides like BMAP27 may serve therapeutic roles in resolving excessive inflammation. Importantly, the variability observed among individual animals emphasizes the need for personalized approaches in immunomodulation. Overall, this study provides novel insights into the immunological functions of bovine HDPs, supporting their potential as alternatives or adjunctive therapies to antibiotics in veterinary medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.